Agreed. Worth going back and looking at Canaccord's buy recommendation for MYX earlier this year in April/May also. They had price target of $0.75 but reasonably conservative revenue assumptions for Tolsura, Myring and E4. They also valued MCS division at $0.34 on its own! I thought the valuation methodology and commentary was the most balanced I'd seen on MYX in some time - not overly bullish, but not dire straights either. It's tough times right now, but this should come good. I spoke to investor relations again and they said the 5 new Novast products will be launched across FY21 (one still pending at FDA) and the other $200m new WH generic awaiting FDA approval this calendar year still has no generic competitors. If the approvals fall our way, revenue could scale up quite quickly...
MYX Price at posting:
34.8¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)